Medovir Special Precautions

Carcinogenicity: Acyclovir was not found to be carcinogenic in long-term studies in the rat and the mouse.
Mutagenicity: The results of a wide range of mutagenicity test in vitro and in vivo indicate that acyclovir does not pose a genetic risk to man.
Impairment of Fertility: Largely reversible adverse effects on spermatogenesis in association with overall toxicity in rats and dogs have been reported only at doses of acyclovir greatly in excess of those employed therapeutically.
Two generation studies in mice did not reveal any effect of orally administered acyclovir on fertility.
There is no experience on the effect of Medovir on human female fertility.
Medovir has been shown to have no definitive effect upon sperm count, morphology or motility in man.
Use in pregnancy & lactation: Systemic administration of acyclovir did not produce embryotoxic or teratogenic effects in rabbits or rats.
Experience in humans is limited, so the use of acyclovir should be considered only when the potential benefits outweigh the possibility of unknown risks. Limited human data show that Medovir does pass into breast milk.